Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies
Go back to Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies| Gilead Sciences (NASDAQ: GILD) | Delayed: 126.34 +0.01 (0.01%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $126.33 | 52 Week High | $108.63 | |||
| Open | $125.88 | 52 Week Low | $71.39 | |||
| Day High | $127.27 | P/E | 69.80 | |||
| Day Low | $124.19 | EPS | $1.81 | |||
| Volume | 7,409,568 | |||||
| (NYSE: RCUS) | Delayed: 30.83 -0.25 (0.8%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $31.08 | 52 Week High | $ | |||
| Open | $31.14 | 52 Week Low | $ | |||
| Day High | $31.74 | P/E | N/A | |||
| Day Low | $30.59 | EPS | $ | |||
| Volume | 1,344,885 | |||||
